ArticleParasites & vectors2020
Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo.
Article in Parasites & vectors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- A Two-Phase Approach to the Use of Tafenoquine Was Associated with Cure of Babesiosis in Two Immunocompromised Patients with Relapsing Babesiosis.Pathogens (Basel, Switzerland) · 2026Article
- Article
- Tafenoquine for Relapsing Babesiosis: A Case Series.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Comparative chemical genomics inProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.The Journal of infectious diseases · 2024Article
- Unrevealing the therapeutic potential of artesunate against emerging zoonoticFrontiers in veterinary science · 2024Article
- Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with AcutePathogens (Basel, Switzerland) · 2023Article
- The Use of Natural Bioactive Nutraceuticals in the Management of Tick-Borne Illnesses.Microorganisms · 2023Review
- Why is Babesia not killed by artemisinin like Plasmodium?Parasites & vectors · 2023Article
- Failure of an Approximately Six Week Course of Tafenoquine to Completely EradicatePathogens (Basel, Switzerland) · 2022Article
- Inhibitory effect of naphthoquine phosphate on Babesia gibsoni in vitro and Babesia rodhaini in vivo.Parasites & vectors · 2022Article
- Epitope profiling of monoclonal antibodies to the immunodominant antigen BmGPI12 of the human pathogenFrontiers in cellular and infection microbiology · 2022Article
- Article
- Treatment of Human Babesiosis: Then and Now.Pathogens (Basel, Switzerland) · 2021Review
- Tafenoquine Is a Promising Drug Candidate for the Treatment of Babesiosis.Antimicrobial agents and chemotherapy · 2021Article
- Botanical Medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia Demonstrate Inhibitory Activity Against Babesia duncani.Frontiers in cellular and infection microbiology · 2021Article
- Case Report: OverwhelmingOpen forum infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundBabesiosis represents a veterinary and medical threat, with a need for novel drugs. Artemisinin-based combination therapies (ACT) have been successfully implemented for malaria, a human disease caused by related parasites, Plasmodium spp. The aim of this study was to investigate whether ACT is active against Babesia in vitro and in vivo.
methodsMefloquine, tafenoquine, primaquine, methylene blue and lumefantrine, alone or in combination with artesunate, were tested in vitro against Babesia bovis. Parasite growth was verified using a SYBR green I-based fluorescence assay. Mice infected with Babesia microti were treated with mefloquine or tafenoquine, alone or in combination with artesunate, and parasitemia was verified by microscopy and PCR.
resultsAll drugs, except lumefantrine, showed in vitro activity against B. bovis, with methylene blue showing the most potent activity (concentration 0.2 μM). Combination with artesunate led to improved activity, with mefloquine showing a striking 20-fold increase in activity. Tafenoquine (10 mg/kg, base), combined or not with artesunate, but not mefloquine, induced rapid clearance of B. microti in vivo by microscopy, but mice remained PCR-positive. Blood from mice treated with tafenoquine alone, but not with tafenoquine-artesunate, was infective for naive mice upon sub-inoculation.
conclusionsTafenoquine, and most likely other 8-aminoquinoline compounds, are promising compounds for the development of ACT for babesiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.